We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Study of DPX-Survivac Vaccine Therapy and Epacadostat in Patients With Recurrent Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02785250
Recruitment Status : Recruiting
First Posted : May 27, 2016
Last Update Posted : June 14, 2017
Incyte Corporation
Information provided by (Responsible Party):
ImmunoVaccine Technologies, Inc.

Brief Summary:
Immunotherapeutic survivin vaccine DPX-Survivac, low dose oral cyclophosphamide, and IDO1 inhibitor epacadostat will be tested together for the first time in patients with recurrent ovarian, fallopian tube, or peritoneal cancer to determine the safety and potential immune-modulating activity of the combination of these agents.

Condition or disease Intervention/treatment Phase
Recurrent Epithelial Ovarian Cancer Recurrent Fallopian Tube Cancer Recurrent Peritoneal Cancer Biological: DPX-Survivac Drug: Cyclophosphamide Drug: Epacadostat (INCB024360) Phase 1

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients With Recurrent Ovarian Cancer
Study Start Date : April 2016
Estimated Primary Completion Date : May 2018
Estimated Study Completion Date : May 2018

Arm Intervention/treatment
Experimental: Experimental
DPX-Survivac, Cyclophosphamide, Epacadostat
Biological: DPX-Survivac
SubQ injection
Drug: Cyclophosphamide
Drug: Epacadostat (INCB024360)

Primary Outcome Measures :
  1. Safety as measured by adverse event reporting (CTCAE) [ Time Frame: up to 13 months ]
  2. Cell mediated immunity as measured by the antigen specific response in peripheral blood [ Time Frame: bimonthly for up to 13 months ]
  3. Evaluation of treatment-induced changes in tumor infiltrating lymphocytes [ Time Frame: at 8 to 10 weeks ]

Secondary Outcome Measures :
  1. Objective Response Rate [ Time Frame: up to 13 months ]
    Evaluated using modified RECIST v1.1

  2. Duration of Response [ Time Frame: up to 13 months ]
  3. Time to Progression [ Time Frame: up to 13 months ]
  4. Overall Survival [ Time Frame: up to 13 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Histologically confirmed stage IIc-IV epithelial ovarian, fallopian tube or peritoneal cancer
  • Platinum-resistant or -sensitive after completing first-line treatment (debulking surgery and adjuvant or neoadjuvant treatment with standard of care treatment such as carboplatin and paclitaxel). Subjects may have had any number of subsequent lines of chemotherapy.
  • Must have evidence of progressive disease with biochemical (i.e. rising CA-125) and/or radiologic progression
  • Must have measurable disease by RECIST v1.1, a successful pre-treatment tumor biopsy, and be willing to undergo tumor biopsy during treatment
  • Ambulatory with an ECOG 0-1
  • Life expectancy ≥ 6 months
  • Meet protocol-specified lab requirements

Key Exclusion Criteria:

  • Eligible for otherwise curative treatment or undergoing concurrent therapy
  • Prior receipt of survivin based vaccines or immune checkpoint inhibitors (e.g. anti-CTLA-4, anti-PD-1, anti-PD-L1, or any other antibody or drug specifically targeting T cell co-stimulation) or an IDO inhibitor
  • Concurrent second malignancy other than non-melanoma skin cancer, cervical carcinoma in situ, or controlled bladder cancer
  • Clinical ascites or metastatic pleural fluid
  • Malignant bowel obstruction
  • History of autoimmune disease requiring treatment within the last two years (except vitiligo or diabetes)
  • Recent history of thyroiditis
  • Presence of a serious acute infection or chronic infection
  • Active central nervous system (CNS) or leptomeningeal metastasis (brain metastases)
  • GI condition that might limit absorption of oral agents
  • Other serious intercurrent chronic or acute illness, including myocardial infarction or cerebrovascular event within 6 months
  • Ongoing treatment with steroid therapy or other immunosuppressive
  • Receipt of monoamine oxidase inhibitors (MAOIs), UGT1A9 inhibitors, or melatonin supplements
  • Acute or chronic skin and/or microvascular disorders
  • Edema or lymphedema in the lower limbs > grade 2

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02785250

United States, California
Stanford University Recruiting
Palo Alto, California, United States, 94304
Contact: Dona Bahmani    650-724-3308    dbahmani@stanford.edu   
United States, New York
Lenox Hill Hospital Recruiting
New York, New York, United States, 10028
Contact: Jeannine Villella, DO       jvillella@northwell.edu   
Contact: Sangmi Lee, RN, MSN    212-434-4482    slee52@northwell.edu   
United States, Oregon
Oregon Health & Sciences University, Knight Cancer Institute Recruiting
Portland, Oregon, United States, 97239
Contact: Knight Clinical Trials Information Line    503-494-1080    trials@ohsu.edu   
Principal Investigator: Tanja Pejovic, MD         
United States, Pennsylvania
University of Pennsylvania Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Cathi Lee Ybarra, BSN    215-614-0234      
United States, Texas
Mary Crowley Cancer Research Center Recruiting
Dallas, Texas, United States, 75230
Contact: Referral Office    972-566-3000    referral@marycrowley.org   
Principal Investigator: John Nemunaitis, MD         
Canada, Ontario
Princess Margaret Hospital Recruiting
Toronto, Ontario, Canada, M5G 2M9
Contact: Amit Oza, MD    416-946-2818    amit.oza@uhn.ca   
Sponsors and Collaborators
ImmunoVaccine Technologies, Inc.
Incyte Corporation

Responsible Party: ImmunoVaccine Technologies, Inc.
ClinicalTrials.gov Identifier: NCT02785250     History of Changes
Other Study ID Numbers: ONC-DPX-Survivac-06
First Posted: May 27, 2016    Key Record Dates
Last Update Posted: June 14, 2017
Last Verified: June 2017

Keywords provided by ImmunoVaccine Technologies, Inc.:
IDO1 inhibitor
fallopian tube

Additional relevant MeSH terms:
Ovarian Neoplasms
Fallopian Tube Neoplasms
Neoplasms, Glandular and Epithelial
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Fallopian Tube Diseases
Neoplasms by Histologic Type
Immunologic Factors
Physiological Effects of Drugs
Immunosuppressive Agents
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists